Suche
  • ODI Pharma

Communique from the Annual General Meeting in ODI Pharma AB (publ)

This is an unofficial translation of a communique from the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail.


Today, on the 14th of December, the Annual General Meeting (“AGM”) in ODI Pharma AB (publ) was held. Below follows a summary of the resolutions. All decisions were taken with the required majority.


Allocation of the company’s profit or loss (paragraph 9b)

The AGM resolved to dispose the company's results according to the Board's proposal in the annual report. The AGM also decided that no dividend shall be paid for the financial year 2020.


Determination of fees for members of the board of directors and auditors (paragraph 11)

The AGM resolved that board remuneration should amount to 100,000 SEK for the Chairman of the board Volker Wiederrich, and 100,000 SEK each for the board members Derek Simmross and Karina Kilinski. In addition, the AGM decided that board remuneration should amount to 75,000 SEK for the board member Gösta Lidén.


Furthermore, the AGM decided that an auditor and no deputy auditor should be appointed and that auditors' fees should be paid according to approved invoice in accordance with customary charging standards.


Election of the board of directors and accounting firm or auditor (paragraph 12)

The AGM decided to re-elect Derek Simmross, Karina Kilinski och Gösta Lidén as ordinary board members. It was decided to re-elect Volker Wiederrich as Chairman of the Board. Furthermore, the AGM decided to re-elect the company's audit firm Örhlings PricewaterhouseCoopers with auditor-in-charge Johan Engstam until the end of the Annual General Meeting that will be held next financial year.

Resolvement to amend the Articles of Association (paragraph 13)

The AGM resolved to amend the articles of association according to below:


Current wording

§3 Verksamhet


Bolaget ska direkt eller indirekt genom dotterbolag bedriva produktion av läkemedel och medicinska produkter och därmed förenlig verksamhet. Bolaget ska också genomföra styrning av sina dotterbolag. Bolaget ska även förvalta fast egendom.

The Company shall directly or indirectly through its subsidiaries carry out operations within the production of pharmaceuticals and medical products, and related activities. The Company shall also carry out the governance of its subsidiaries. The Company shall also manage related properties

Proposed wording


§3 Verksamhet


Bolaget ska direkt eller indirekt genom dotterbolag bedriva produktion av läkemedel och medicinska produkter och produktion av förpackade konsumentprodukter relaterade till dessa läkemedel och medicinska produkter, och därmed förenlig verksamhet. Bolaget ska också genomföra styrning av sina dotterbolag. Bolaget ska även förvalta fast egendom.

The Company shall directly or indirectly through its subsidiaries carry out operations within the production of pharmaceuticals and medical products and production of consumer-packaged goods related to those pharmaceutical and medical products, and related activities. The Company shall also carry out the governance of its subsidiaries. The Company shall also manage related properties.





Stockholm in December 2020

ODI Pharma AB (publ)

THE BOARD


For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com



ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.



201211 - ODI - Communique from Annual Ge
.
Download • 234KB

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Publication of half-year report 2020

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2020. The report is available as an attached document to this press release and on the Compa

ODI Pharma achieves milestone towards market entry in Poland

ODI Pharma AB (“ODI” or the “Company”) announces that its subsidiary ODI Pharma Polska Sp. z o.o. has finalized documentation and filed the application to obtain a marketing authorization for the sale

ODI Pharma proceeds with its plans and launches Project Skin

ODI Pharma AB (“ODI” or “the Company”) announces that the Board of Directors has decided to expand ODI’s current business with specialized, highly CBD-infused skin care products (“Project Skin”). The

White on Transparent.png

© 2019 by ODI Pharma AB

  • Twitter